Citation Impact
Citing Papers
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
2021
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer
2012
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
2011 Standout
Neoadjuvant Therapy in the Treatment of Breast Cancer
2014
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer
2003
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
2011
The therapeutic potential of interleukin-6 hyperagonists and antagonists
1997
Targeted therapies in breast cancer: are heart and vessels also being targeted?
2012
Breast cancer
2016 Standout
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
Strategies for minimizing complications of neutropenia: Prophylactic myeloid growth factors or antibiotics
2009
Almost all articles on cancer prognostic markers report statistically significant results
2007
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
2008
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
2009
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
2011
Osteomyelitis
1997 Standout
Autoimmune diseases caused by defects in clearing dead cells and nuclei expelled from erythroid precursors
2007
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
1998 Standout
Toxicogenomics for the Prediction of Toxicity Related to Herbs from Traditional Chinese Medicine
2010
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
2012
Tissue-resident macrophages
2013 Standout
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study
2008
A multigenic program mediating breast cancer metastasis to bone
2003 Standout
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
2017
Optimal Dosing of Atypical Antipsychotics in Adults: A Review of the Current Evidence
2002
Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells.
1996
Significance, detection and markers of disseminated breast cancer cells
2006
Do Pressures to Publish Increase Scientists' Bias? An Empirical Support from US States Data
2010 Standout
The landscape of long noncoding RNAs in the human transcriptome
2015 Standout
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Bone Marrow, Cytokines, and Bone Remodeling — Emerging Insights into the Pathophysiology of Osteoporosis
1995
Dose Response and Dose Equivalence of Antipsychotics
2004
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
1999 StandoutNature
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Differential Gene Expression of TGF-β Family Members and Osteopontin in Breast Tumor Tissue: Analysis by Real-Time Quantitative PCR
2002
Deep learning in histopathology: the path to the clinic
2021 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
2006
Value of endometrial thickness measurement for diagnosing focal intrauterine pathology in women without abnormal uterine bleeding
2009
Ki67 assessment in breast cancer: an update
2017
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
2007
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival
2010
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Pharmacogenetics of bipolar disorder
2002
Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6
1998 StandoutNobel
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
2012
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Antiangiogenic therapy in oncology: current status and future directions
2016
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
2003 Standout
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
2008 Standout
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
2014
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
2012 StandoutNobel
Plasma Fluoride Level as a Predictor of Voriconazole-Induced Periostitis in Patients With Skeletal Pain
2014
Docetaxel-related side effects and their management
2009
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy
2009
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis
2014
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
2011
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
2006
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy
2012
Surgical treatment of primary breast cancer in the neoadjuvant setting
2014
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis*
2000 Standout
Tamoxifen Versus Control After Adjuvant, Risk-Adapted Chemotherapy in Postmenopausal, Receptor-Negative Patients With Breast Cancer: A Randomized Trial (GABG-IV D-93)—The German Adjuvant Breast Cancer Group
2005
Activation of the Janus Kinase/STAT (Signal Transducer and Activator of Transcription) Signal Transduction Pathway by Interleukin-6-Type Cytokines Promotes Osteoblast Differentiation*
1997
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Alemtuzumab for patients with chronic lymphocytic leukaemia
2012
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
2009
Pluripotency and nuclear reprogramming
2008 StandoutNobel
Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues
1997 StandoutScience
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
2006
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Leukemia-Inhibitory Factor—Neuroimmune Modulator of Endocrine Function*
2000
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis
1996 StandoutNobel
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Variation in CYP1A2 Activity and its Clinical Implications: Influence of Environmental Factors and Genetic Polymorphisms
2008
Works of B. Gerber being referenced
Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole
2012
Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
2013
Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIα-status of the primary tumor?
2005
Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)
2013
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study
2004
Recombinant Human Leukemia Inhibitory Factor Is Mitogenic for Human Bone-Derived Osteoblast-like Cells
1994
Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
2007
Human chorionic gonadotrophin-beta transcripts correlate with progesterone receptor values in breast carcinomas
2000
Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding
2001
Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study
2008
Erythroblastic islands
2010
Complementary and alternative therapeutic approaches in patients with early breast cancer: a systematic review
2005
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro)
2013
Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial
2008
VEGF-A promotes intussusceptive angiogenesis in the developing chicken chorioallantoic membrane
2010
Comparative Analysis Between the HER2 Status in Primary Breast Cancer Tissue and the Detection of Isolated Tumor Cells in the Bone Marrow
2004
Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 trial
2004
Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) in breast cancer patients
2005
Abstract S3-1: Neoadjuvant Chemotherapy in the very young 35 years of age or younger
2012
RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy.
2011
Pegfilgrastim alone or with ciproflaxin significantly reduces febrile neutropenia and hospitalization vs G-CSF alone in breast cancer patients receiving neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC)
2006
S5-4: pCR as a Surrogate in HER2−Positive Patients Treated with Trastuzumab.
2011
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.
1994
Association of persistence of isolated tumor cells (ITC) in bone marrow (BM) of breast cancer patients with risk for relapse
2004
Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis.
2011
[Effectiveness of perioperative preventive use of antibiotics with ampicillin/gentamycin or cefotiam in abdominal cesarean section].
1989
Primary endpoint analysis of the GEPARDUO study: Comparing dose-dense with sequential adriamycin/docetaxel combination as preoperative chemotherapy (PCHT) in operable breast cancer (T2-3, N0-2, M0)
2003
PD07-05: Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/− Trastuzumab Containing Chemotherapy.
2011
Abstract S3-1: Lapatinib vs Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO STUDY (GBG 44)
2010